Jennifer Lafontaine Ph.D.
Vice President, Head of Oncology Medicinal Chemistry, Pfizer
Jennifer Lafontaine currently serves as the Head of Oncology Medicinal Chemistry at Pfizer in LaJolla, CA, where her team's focus is to discover and advance transformational cancer therapies for patients as quickly as possible by leveraging their expertise in small molecule design, synthesis, protein sciences, and structural biology. Jennifer previously led the Oncology Medicinal Chemistry Synthesis and Analytical Sciences group, a lab-based team responsible for the delivery of candidates for discovery Oncology projects.
Jennifer previously served as Director of Ophthalmology Chemistry, leading medicinal chemistry efforts targeting diseases of the eye, delivering several therapies to the clinic including Vyzulta® and taprenepag.
Jennifer earned her B.A. in chemistry from Swarthmore College, and then received her Ph.D. in synthetic organic chemistry from the University of California, Berkeley, before joining Pfizer in 1993.